Prostate Cancer News

The Lancet Commission on prostate cancer projects that annual global cases will double from 1.4 million in 2020 to 2.9 million by 2040, with deaths rising 85% to nearly 700,000, mainly in low- and middle-income countries, and calls for improved early detection programs, increased awareness, expanded treatment capacity, and more research on ethnic disparities.

The combination of cabozantinib and atezolizumab significantly improved progression-free survival compared to second-line hormone therapy in patients with metastatic castration-resistant prostate cancer that progressed after initial hormone therapy in the CONTACT-02 trial.

The American Cancer Society's Facts & Figures report provides vital insights for 2024, where the U.S. faces a surge in cancer cases, urging attention to early detection, especially in prostate cancer. Disparities persist, underscoring the need for equity.

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer.

Dr. Alicia Morgans emphasizes the importance of educating prostate cancer patients and caregivers through trusted resources, like the Prostate Cancer Foundation and ZERO Prostate Cancer, and encourages open communication with medical teams, addressing topics such as cancer curability, treatment options, sexual health, mental health, and the need for support in the context of prostate cancer care.

A new bill in D.C. aims to reduce high prostate cancer fatality rates, especially among black men, by mandating annual insurance coverage for prostate cancer screenings, addressing disparities in access to testing and improving early diagnosis for better survival rates.

Prostate cancer screening methods are under review for better targeting high-risk groups and addressing stagnant death rates and late-stage diagnoses.

More men with prostate cancer could afford to delay their treatment, a decades-long study has found, suggesting that active monitoring by health-care professionals is an equally valid — and less harsh — option.